Published in Am J Pathol on July 20, 2012
Krüppel-like factors in cancer. Nat Rev Cancer (2013) 1.32
Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. RNA Biol (2014) 0.87
Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy. Cancer Metastasis Rev (2014) 0.82
Alternative splicing programs in prostate cancer. Int J Cell Biol (2013) 0.81
The Krüppel-like factors in female reproductive system pathologies. J Mol Endocrinol (2015) 0.77
Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy. Curr Opin Urol (2013) 0.76
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. EBioMedicine (2017) 0.75
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet (2008) 24.51
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Krüppel-like factors: three fingers in many pies. J Biol Chem (2001) 5.05
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (2001) 3.22
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res (2004) 1.57
Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol (2003) 1.50
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Alternative splicing and tumor progression. Curr Genomics (2008) 1.43
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest (2008) 1.36
KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem (2008) 1.23
E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene (2006) 1.22
CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer. Bioinformatics (2011) 1.18
Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res (2001) 1.18
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol (2008) 1.12
Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol (2006) 1.03
Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One (2010) 0.99
Caffeine regulates alternative splicing in a subset of cancer-associated genes: a role for SC35. Mol Cell Biol (2007) 0.99
Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br J Cancer (2003) 0.91
The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. J Hepatol (2010) 0.86
Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Prostate (2010) 0.86
Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6. Prostate (2006) 0.85
Alternative splicing interference by xenobiotics. Toxicology (2012) 0.85
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA (2013) 3.40
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet (2002) 3.10
Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am J Hum Genet (2010) 2.54
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
The development of common data elements for a multi-institute prostate cancer tissue bank: the Cooperative Prostate Cancer Tissue Resource (CPCTR) experience. BMC Cancer (2005) 2.35
Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology (2012) 2.18
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood (2010) 2.05
An informatics model for tissue banks--lessons learned from the Cooperative Prostate Cancer Tissue Resource. BMC Cancer (2006) 1.97
The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue Bank. BMC Cancer (2008) 1.88
Retracted A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2008) 1.84
Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax (2010) 1.80
Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol (2007) 1.77
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell (2009) 1.77
The tissue microarray data exchange specification: implementation by the Cooperative Prostate Cancer Tissue Resource. BMC Bioinformatics (2004) 1.74
Retracted The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene. Hum Gene Ther (2009) 1.70
Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging (2010) 1.70
Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res (2005) 1.68
Multilocular cystic renal cell carcinoma: comparison of imaging and pathologic findings. AJR Am J Roentgenol (2012) 1.54
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma (2014) 1.53
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res (2008) 1.52
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52
Mifepristone inhibits GRβ coupled prostate cancer cell proliferation. J Urol (2012) 1.51
Aggressive angiomyxoma of male genital region. Report of 4 cases with immunohistochemical evaluation including hormone receptor status. Ann Diagn Pathol (2006) 1.41
Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol (2002) 1.41
Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. Proc Natl Acad Sci U S A (2008) 1.40
Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem (2005) 1.38
A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome. N Engl J Med (2003) 1.38
Functioning adrenocortical oncocytoma: a case report and review of the literature. Ann Diagn Pathol (2005) 1.34
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res (2009) 1.34
Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res (2005) 1.29
5-Hydroxymethylcytosine: a new kid on the epigenetic block? Mol Syst Biol (2011) 1.29
Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res (2008) 1.28
Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res (2012) 1.26
Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2008) 1.23
Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. Am J Hum Genet (2010) 1.21
Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res (2006) 1.20
Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res (2003) 1.19
Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases. Am J Surg Pathol (2005) 1.19
Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. AJR Am J Roentgenol (2010) 1.18
Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod (2005) 1.15
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. Radiology (2012) 1.12
Growth hormone receptor regulates β cell hyperplasia and glucose-stimulated insulin secretion in obese mice. J Clin Invest (2011) 1.12
Urinary bladder adenocarcinoma arising in a spina bifida patient. Ann Diagn Pathol (2007) 1.11
Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res (2010) 1.11
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res (2010) 1.11
mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am (2012) 1.11
Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex. Cancer Res (2008) 1.10
Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest (2012) 1.09
Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med (2008) 1.09
Low-grade mucosa-associated lymphoid tissue lymphoma involving the kidney: report of 3 cases and review of the literature. Arch Pathol Lab Med (2006) 1.07
Metastatic tumors to the urinary bladder: clinicopathologic study of 11 cases. Int J Surg Pathol (2011) 1.06
Diffusion-weighted intravoxel incoherent motion imaging of renal tumors with histopathologic correlation. Invest Radiol (2012) 1.05
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S. Arch Pathol Lab Med (2008) 1.05
3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol (2004) 1.05
Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy. Rev Urol (2009) 1.05
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol (2010) 1.05
North African Jewish and non-Jewish populations form distinctive, orthogonal clusters. Proc Natl Acad Sci U S A (2012) 1.05
PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol (2006) 1.04
MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR Am J Roentgenol (2010) 1.04
Gonadal tumor with granulosa cell tumor features in an adult testis. Ann Diagn Pathol (2002) 1.04
Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer. Radiology (2012) 1.04
Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene (2004) 1.04
Localized cystic disease of the kidney: distinction from cystic neoplasms and hereditary polycystic diseases. Am J Surg Pathol (2013) 1.04
Utility of the apparent diffusion coefficient for distinguishing clear cell renal cell carcinoma of low and high nuclear grade. AJR Am J Roentgenol (2010) 1.03
Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol (2006) 1.03
EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther (2008) 1.03
Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism (2011) 1.02
Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol (2010) 1.02
Prostate cancer: multiparametric MRI for index lesion localization--a multiple-reader study. AJR Am J Roentgenol (2012) 1.01
Intraepidermal and dermal Merkel cell carcinoma with squamous cell carcinoma in situ: a case report with review of literature. J Cutan Pathol (2009) 1.01
Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol (2006) 1.01
Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther (2007) 0.99
Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med (2010) 0.99
Characterization of malignancy of adnexal lesions using ADC entropy: comparison with mean ADC and qualitative DWI assessment. J Magn Reson Imaging (2012) 0.99
Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol (2009) 0.98
No major association between TGFBR1*6A and prostate cancer. BMC Genet (2004) 0.98
Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with caucasian prostate cancer patients. Clin Cancer Res (2004) 0.97
Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging (2014) 0.97
Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin North Am (2012) 0.97
Intratesticular mucinous cystadenoma: immunohistochemical comparison with ovarian and colonic tissue. Arch Pathol Lab Med (2005) 0.96
Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist (2005) 0.96
Management of localized prostate cancer and an incidental ureteral duplication with upper pole ectopic ureter inserting into the prostatic urethra. Rev Urol (2008) 0.95
Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging (2011) 0.95
The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy. J Urol (2003) 0.94
Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci (2006) 0.94